Trial reportThe Journal of clinical endocrinology and metabolism2014
Effects of escitalopram on markers of bone turnover: a randomized clinical trial.
Trial report in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis.European journal of clinical pharmacology · 2020Pooled it
- Antidepressant Use and Risk of Reoperation After Distal Radius Open Reduction and Internal Fixation: A Propensity Score-Matched Cohort Study.Journal of hand surgery global online · 2026Article
- The selective serotonin reuptake inhibitor escitalopram oxalate negatively impacts the fracture healing in healthy adults and in osteoporotic rats.Scientific reports · 2025Article
- The risk of fracture among women starting selective serotonin reuptake inhibitors.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- DNA methylation of bone morphogenetic protein 7 in leukocytes as a possible biomarker for hand osteoarthritis: A pilot study.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
- Effects of fish oil supplementation on bone turnover markers in depression: a pilot study.Frontiers in nutrition · 2024Article
- Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress.Molecular medicine (Cambridge, Mass.) · 2022Article
- Premenopausal Singaporean Women Suffering from Major Depressive Disorder Treated with Selective Serotonin Reuptake Inhibitors Had Similar Bone Mineral Density as Compared with Healthy Controls.Diagnostics (Basel, Switzerland) · 2022Article
- Lights on MsFLASH: a review of contributions.Menopause (New York, N.Y.) · 2020Review
- Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study.Journal of bone and mineral metabolism · 2019Article
- Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model.International journal of oral science · 2018Article
- Could use of Selective Serotonin Reuptake Inhibitors During Lactation Cause Persistent Effects on Maternal Bone?Journal of mammary gland biology and neoplasia · 2018Review
- Article
- Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms.Osteoporosis and sarcopenia · 2017Review
- Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect.Nature medicine · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
contextRecent observational studies have suggested that the use of selective serotonin reuptake inhibitors is associated with an increased fracture risk and an accelerated bone loss, although conflicting results have been reported. Furthermore, because many of these studies have been performed in depressed women, confounding by indication may influence these findings.
objectiveThe objective of the study was to determine whether selective serotonin reuptake inhibitors affect bone metabolism Design: This was a randomized controlled trial.
settingThe study was conducted in four US clinical sites.
participantsHealthy peri- and postmenopausal women participated in the study.
interventionThe intervention was escitalopram (10-20 mg/d) for the treatment of vasomotor symptoms.
main outcome measuresSerum carboxyterminal collagen crosslinks (CTX) and serum amino-terminal propeptide of type I collagen (P1NP) were measured.
resultsOne hundred forty-one peri- or postmenopausal nondepressed women (mean age 53.7 y, SD 4.1) had baseline and 8-week follow-up samples available for analysis and were included in the study (69 escitalopram, 72 placebo). The groups were balanced across a broad range of baseline characteristics, including age, race, body mass index, smoking status, and mood symptoms. The between-group differences in the change in CTX and P1NP from baseline to week 8 were compared by a repeated-measures linear regression model adjusted for race, clinical center, and baseline measurement. Treatment with escitalopram reduced serum P1NP by 1.02 ng/mL on average [95% confidence interval (CI) -5.17, 3.12] compared with a reduction of 1.88 ng/mL (95% CI -4.82, 1.06) in the placebo group (P = .65). Similarly, serum CTX decreased 0.02 ng/mL on average (95% CI -0.05, 0.01) in the escitalopram group compared with 0.00 ng/mL (95% CI -0.02, 0.02) in the placebo group (P = .24). The results were similar when the analysis was restricted to those women whose adherence to study medication was 70% or greater.
conclusionsAlthough the study was limited to 8 weeks, these results suggest that escitalopram does not significantly alter bone metabolism in the short term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.